What the company does
Qurient is a South Korean biotech that develops entirely new prescription drugs, medicines with novel mechanisms not previously approved, targeting cancer, bacterial infections, and inflammatory diseases.
It is listed on KOSDAQ, South Korea's tech-focused stock exchange, and operates two business lines: drug research and development, and the distribution of prescription pharmaceuticals. The company's pipeline programs are all first-in-class candidates, and it earns revenue through a combination of research-and-development service fees and pharmaceutical distribution sales.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$6.5M
- FY2024US$6.7M
- FY2025US$5.1M
Operating profit
- FY2023−US$16.8M
- FY2024−US$19.9M
- FY2025−US$21.6M
Net income
- FY2023−US$16.1M
- FY2024−US$18.1M
- FY2025−US$22.7M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Qurient was spun off from the Korea Institut Pasteur and holds a strategic alliance with Germany's Max-Planck-Gesellschaft giving it priority review rights over cancer and autoimmune research programs.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?